Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025World Journal of Clinical Oncology

Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTing ZhengFujian Medical UniversityXLXingxing LiJinhua Academy of Agricultural SciencesLZLi ZhouJiangnan University

Discussion

Loading...

Member takes

Implication

Meta-analysis evaluates the addition of PD-1/L1 inhibitors to standard therapy for mCRC, suggesting limited survival benefits.

Key Points

  • Combining PD-1/L1 inhibitors with SOC therapy showed no significant improvement in overall survival for metastatic colorectal cancer patients.
  • Analysis highlighted a notable advantage in progression-free survival for the combined treatment group versus SOC alone, with an HR of 0.8 (P = 0.033).
  • Evaluated data stemmed from six randomized controlled trials enrolling 675 participants, underscoring the need for further validation in future studies.
  • Integration of PD-1/L1 inhibitors revealed manageable toxicity, yet did not enhance overall response rates or survival outcomes for patients with MSS/pMMR.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/68af4eb4ad7bf08b1ead7556https://doi.org/10.5306/wjco.v16.i8.106873
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity2010 · 1,254 citations
  2. 2Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial2024 · 74 citations
  3. 3Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis2024 · 6 citations
  4. 4Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective2022 · 54 citations
  5. 5First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study2021 · 716 citations